Bristol Myers Squibb Co. (BMY)
66.82
+0.01
(+0.01%)
USD |
NYSE |
Sep 01, 15:21
Bristol Myers Squibb Research and Development Expense (Annual) : 9.492B for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 9.492B |
| December 31, 2024 | 9.782B |
| December 31, 2023 | 9.207B |
| December 31, 2022 | 9.411B |
| December 31, 2021 | 9.533B |
| December 31, 2020 | 9.557B |
| December 31, 2019 | 5.949B |
| December 31, 2018 | 5.131B |
| December 31, 2017 | 4.969B |
| December 31, 2016 | 4.405B |
| December 31, 2015 | 4.037B |
| December 31, 2014 | 4.043B |
| December 31, 2013 | 3.731B |
| December 31, 2012 | 3.904B |
| December 31, 2011 | 3.839B |
| December 31, 2010 | 3.566B |
| December 31, 2009 | 3.647B |
| December 31, 2008 | 3.224B |
| December 31, 2007 | 3.12B |
| December 31, 2006 | 2.906B |
| December 31, 2005 | 2.674B |
| December 31, 2004 | 2.442B |
| December 31, 2003 | 2.177B |
| Date | Value |
|---|---|
| December 31, 2002 | 2.206B |
| December 31, 2001 | 2.183B |
| December 31, 2000 | 1.939B |
| December 31, 1999 | 1.843B |
| December 31, 1998 | 1.577B |
| December 31, 1997 | 1.385B |
| December 31, 1996 | 1.276B |
| December 31, 1995 | 1.199B |
| December 31, 1994 | 1.108B |
| December 31, 1993 | 1.128B |
| December 31, 1992 | 1.083B |
| December 31, 1991 | 993.00M |
| December 31, 1990 | 881.00M |
| December 31, 1989 | 789.00M |
| December 31, 1988 | 394.10M |
| December 31, 1987 | 341.70M |
| December 31, 1986 | 311.10M |
| December 31, 1985 | 261.70M |
| December 31, 1984 | 212.40M |
| December 31, 1983 | 185.30M |
| December 31, 1982 | 161.00M |
| December 31, 1981 | 144.00M |
| December 31, 1980 | 128.60M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Johnson & Johnson | 14.83B |
| Eli Lilly & Co. | 13.34B |
| Merck & Co., Inc. | 12.51B |
| Pfizer Inc. | 10.25B |
| AstraZeneca PLC | 13.84B |